🧵 NEW PAPER in @BloodJournal!
Why do IDH1 mutations almost exclusively drive myeloid #leukemia, while IDH2 mutations occur in both myeloid AND lymphoid cancers? #AML#Epigenetics
Despite sharing the same biochemical mechanism, they are NOT equivalent. Here's what we found 👇
Decades of research have revealed the intricacies of how dendritic cells (DCs) function, but fundamental questions remain about how this group of cells develops in humans and how this process goes awry in disease. A thread on our new work! (1/9)
biorxiv.org/content/10.64898…
📢Another exciting seminar on CCEC, scheduled on Friday 6thJun@3PM,UKtime with Alvaro Rada Iglesias @IBBTEC Cantabria.
Alvaro will discuss: Enhancer-Promoter contact, a key feature in gene regulation, how and why?? link2join us06web.zoom.us/webinar/regi…@ShuchiChromaBio@activemotif
🧵 NEW PAPER in @BloodJournal!
Why do IDH1 mutations almost exclusively drive myeloid #leukemia, while IDH2 mutations occur in both myeloid AND lymphoid cancers? #AML#Epigenetics
Despite sharing the same biochemical mechanism, they are NOT equivalent. Here's what we found 👇
Now online: Molecular Plasticity Results in Oncofetal Reprogramming and Therapeutic Vulnerabilities in Juvenile Myelomonocytic Leukemia doi.org/10.1158/2643-3230.BC…
Here, in this @Cancer_Cell mini-review, we highlight recent advances in understanding oncofetal reprogramming and explore its emerging potential as a biomarker and therapeutic target in cancer research. @FGinhouxsciencedirect.com/science/ar…